Literature DB >> 16415465

Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.

Joe T R Clarke1.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 16415465      PMCID: PMC1329458          DOI: 10.1503/cmaj.050706

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  2 in total

1.  Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.

Authors:  J T Clarke; D Amato; R B Deber
Journal:  CMAJ       Date:  2001-09-04       Impact factor: 8.262

Review 2.  Enzyme replacement therapy of Fabry disease.

Authors:  Joe T R Clarke; R Mark Iwanochko
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

  2 in total
  19 in total

1.  Common Drug Review recommendations: an evidence base for expectations?

Authors:  Angela Rocchi; Elizabeth Miller; Robert B Hopkins; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  Policy alternatives for treatments for rare diseases.

Authors:  Abbas H Panju; Chaim M Bell
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

Review 3.  Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.

Authors:  Marianne Rohrbach; Joe T R Clarke
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Orphan drugs policies: a suitable case for treatment.

Authors:  Michael Drummond; Adrian Towse
Journal:  Eur J Health Econ       Date:  2014-05

Review 5.  Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?

Authors:  Devidas Menon; Tania Stafinski; Andrea Dunn; Hilary Short
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

6.  Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.

Authors:  Jesse Elliott; Bláthnaid McCoy; Tammy Clifford; George A Wells; Doug Coyle
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

7.  Qualitative evaluation of the Canadian Fabry Disease Initiative.

Authors:  Mark Embrett; Neil J Mackinnon
Journal:  Can Pharm J (Ott)       Date:  2012-05

8.  Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.

Authors:  Jacques LeLorier; Nugek S B Rawson
Journal:  Can J Cardiol       Date:  2007-07       Impact factor: 5.223

9.  Pricing and reimbursement of orphan drugs: the need for more transparency.

Authors:  Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2011-06-17       Impact factor: 4.123

10.  Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.

Authors:  Laura Gutierrez; Julien Patris; Adam Hutchings; Warren Cowell
Journal:  Orphanet J Rare Dis       Date:  2015-05-03       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.